about Details  1pcs 6ES7195-7HD10-0XA0 Used Servo Drives & Amplifiers

  1. Home
  2. about Details  1pcs 6ES7195-7HD10-0XA0 Used
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Details about   1pcs Used 6ES7195-7HD10-0XA0
Condition: Used: An item that has been used previously. The item may have some signs of cosmetic wear, but is fully Model:

1pcs Used 6ES7195-7HD10-0XA0


Does Not Apply

Type: 1pcs Used 6ES7195-7HD10-0XA0

1pcs Used 6ES7195-7HD10-0XA0


Does not apply

published on tue nov 09 2021

about Details  1pcs 6ES7195-7HD10-0XA0 Used Servo Drives & Amplifiers

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

about Details  1pcs 6ES7195-7HD10-0XA0 Used Servo Drives & Amplifiers

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.